ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0103

CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome

chun Li, Peking University People's Hospital, Beijing, China

Meeting: ACR Convergence 2024

Keywords: antiphospholipid syndrome, Disease Activity, neutrophils

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: To investigate the relationship between CD10highLow-Density Granulocytes (LDG) and disease activity in antiphospholipid syndrome(APS).

Methods: This study included 99 patients with APS who were treated in Peking

University People’s Hospital from November 2022 to April 2024. All patients met the 2006 Sydney classification criteria for APS. At the same time, 27 healthy controls were included. Peripheral blood samples from patients and healthy controls were collected, and LDG(CD14–CD15+CD10high),T helper (Th), T cytotoxic (Tc), Tregulatory (Treg), Th1(TNF-α), Th1(INF-ɣ), Th1(IL-2), Th2(IL-4), Th17(IL-17)

B cells, and NK cells were detected by flow cytometry. The clinical data of CD10highLDG≥3.685% andCD10highLDG< 3.685% were compared. Logistic regression analysis was performed to analyze the risk factors of aGAPSS score ≥10.

Results:  Patients with CD10highLDG≥3.685% had higher aGAPSS (p < 0.001), higher LAC (p =0.039), higher β2GPI (p =0.035), higher prevalence of thrombocytopenia (p =0.017), and triple-positive antiphospholipid antibody (p =0.002). Patients with aGAPSS≥10 had lower platelets (p =0.003), more patients with microvascular (p =0.037), more patients with Coombs-positive (p =0.037), higher CD10highLDG (p =0.024), higher Th cells (p =0.040), higher Th1(INF-ɣ) cells (p =0.029), lower Th2(IL-4) cells (p =0.024)(Figure 1). After treatment, CD10highLDG and aGAPSS decreased significantly in APS patients(Figure 2). Patients with deep venous thromboembolism (p =0.034), thrombocytopenia (p =0.011), SLE-APS (p = 0.041), and patients with double-positive and triple-positive antiphospholipid antibody (p =0.002) had a higher proportion of CD10highLDG.Logistic regression analysis showed that CD10highLDG≥3.685% (OR=9.895, 95%CI=4.000,98.948) were independent risk factors for aGAPSS≥10. ROC curves were drawn for CD10highLDG for disease activity,the areas under the curve was 0.645.

Conclusion: CD10highLDG≥3.685% in peripheral blood mononuclear cells of APS patients is an independent risk factor for aGAPSS score ≥10.It may be an effective indicator to evaluate the activity of APS.

Supporting image 1

Fig 1 Comparison of clinical data of aGAPSS≥10 and aGAPSS<10 groups in APS patients
Treg1:CD4+CD25highCD127low;Treg2:CD3+CD4+CD25highCD127lowCD161+; Treg3:CD3+CD4+CD25highCD127lowCD162+;Treg4:CD4+CD45RA-CXXR5+PD1+CCR7low; Treg5:CD4+CD45RA+; Treg6:CD4+CD25highFoxp3+;
Treg7:CD4+CD25-Foxp3+

Supporting image 2

Fig. 2 Changes of aGAPSS and CD10highLDG in APS patients before and after treatment


Disclosures: c. Li: None.

To cite this abstract in AMA style:

Li c. CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cd10highlow-density-granulocytes-is-a-potential-marker-of-disease-activity-in-antiphospholipid-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd10highlow-density-granulocytes-is-a-potential-marker-of-disease-activity-in-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology